---
schema_version: "secwatch.filing_event.v1"
accession: "0001640266-26-000007"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2026-08-06T20:03:23+00:00"
generated_at: "2026-08-06T20:05:31.396155+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Voyager Q2 net loss narrows to $24.5M; cash $148.8M, runway into 2028; tau programs on track for Q4 data

## Summary
- Net loss $24.5M in Q2 2026 vs $33.4M in Q2 2025; collaboration revenue $3.2M (down from $5.2M).
- Cash, equivalents, and marketable securities $148.8M as of June 30, 2026; expected to fund operations into 2028.
- VY7523 tau PET imaging data expected Q4 2026; VY1706 tau gene therapy IND cleared, dosing expected Q4 2026.
- Neurocrine partner intends to initiate NBIB-223 trial for Friedreich's ataxia in H2 2026 pending FDA IND clearance.
- R&D expenses $22.0M (down from $31.3M) and G&A $7.5M (down from $10.5M) due to prioritization and restructuring.

## SEC filing metadata
- accession: 0001640266-26-000007
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2026-08-06T20:03:23+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000164026626000007/0001640266-26-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000164026626000007/vygr-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640266-26-000007
- JSON: https://secwatch.observer/filing/0001640266-26-000007.json
- Plain text: https://secwatch.observer/filing/0001640266-26-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.